Status:
COMPLETED
Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients
Lead Sponsor:
AstraZeneca
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The primary objective of this study is to evaluate the efficacy of quetiapine fumarate extended-release (XR) used as mono-therapy, administered once daily, in the treatment of schizophrenic patient wi...
Eligibility Criteria
Inclusion
- Schizophrenia diagnosis
- Provision of written informed consent before initiation of any study
Exclusion
- AIDS and hepatitis B
- History of seizure disorder
- Hospitalisation for schizophrenic more than 1 month immediately before enter into study
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
388 Patients enrolled
Trial Details
Trial ID
NCT00882518
Start Date
April 1 2009
End Date
July 1 2010
Last Update
May 15 2012
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Hunan, Changsha, China
2
Research Site
Guangzhou, Guangdong, China
3
Research Site
Baoding, Hebei, China
4
Research Site
Harbin, Heilongjiang, China